- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol...
Adicet Bio Receives $10 Million Product Development Milestone From Regeneron PR Newswire MENLO PARK, Calif., Aug. 5, 2020 MENLO PARK, Calif., Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent...
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform - TrialSpark's integrated tech platform and trial model will enable resTORbio to...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind...
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and VSLR Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, July 24, 2020 NEW YORK, July 24, 2020 /PRNewswire/ -- If...
SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and GCAP Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, July 10, 2020 NEW YORK, July 10, 2020 /PRNewswire/ -- If...
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational...
BOSTON, May 07, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm PR Newswire NEW YORK, May 5, 2020 NEW YORK, May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.